Literature DB >> 22090123

Melanoma differentiation-associated gene 5 is critical for protection against Theiler's virus-induced demyelinating disease.

Young-Hee Jin1, Seung Jae Kim, Eui Young So, Liping Meng, Marco Colonna, Byung S Kim.   

Abstract

Infection of dendritic and glial cells with Theiler's murine encephalomyelitis virus (TMEV) induces various cytokines via Toll-like receptor- and melanoma differentiation-associated gene 5 (MDA5)-dependent pathways. However, the involvement and role of MDA5 in cytokine gene activation and the pathogenesis of TMEV-induced demyelinating disease are largely unknown. In this study, we demonstrate that MDA5 plays a critical role in the production of TMEV-induced alpha interferon (IFN-α) during early viral infection and in protection against the development of virus-induced demyelinating disease. Our results indicate that MDA5-deficient 129SvJ mice display significantly higher viral loads and apparent demyelinating lesions in the central nerve system (CNS) accompanied by clinical symptoms compared with wild-type 129SvJ mice. During acute viral infection, MDA5-deficient mice produced elevated levels of chemokines, consistent with increased cellular infiltration, but reduced levels of IFN-α, known to control T cell responses and cellular infiltration. Additional studies with isolated CNS glial cells from these mice suggest that cells from MDA5-deficient mice are severely compromised in the production of IFN-α upon viral infection, which results in increased cellular infiltration and viral loads in the CNS. Despite inadequate stimulation, the overall T cell responses to the viral determinants were significantly elevated in MDA5-deficient mice, reflecting the increased cellular infiltration. Therefore, the lack of MDA5-mediated IFN-α production may facilitate a massive viral load and elevated cellular infiltration in the CNS during early viral infection, leading to the pathogenesis of demyelinating disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22090123      PMCID: PMC3264388          DOI: 10.1128/JVI.06457-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  A hybrid between a resistant and a susceptible strain of mouse alters the pattern of Theiler's murine encephalomyelitis virus-induced white matter disease and favors oligodendrocyte-mediated remyelination.

Authors:  M C Dal Canto; R W Melvold; B S Kim
Journal:  Mult Scler       Date:  1995-06       Impact factor: 6.312

Review 2.  Antiviral signaling through pattern recognition receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  J Biochem       Date:  2006-12-26       Impact factor: 3.387

3.  Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements.

Authors:  M J Barnden; J Allison; W R Heath; F R Carbone
Journal:  Immunol Cell Biol       Date:  1998-02       Impact factor: 5.126

4.  Type I interferons produced by dendritic cells promote their phenotypic and functional activation.

Authors:  Maria Montoya; Giovanna Schiavoni; Fabrizio Mattei; Ion Gresser; Filippo Belardelli; Persephone Borrow; David F Tough
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

5.  Distinct roles of protein kinase R and toll-like receptor 3 in the activation of astrocytes by viral stimuli.

Authors:  Pamela A Carpentier; Bryan R Williams; Stephen D Miller
Journal:  Glia       Date:  2007-02       Impact factor: 7.452

6.  Induction of chemokine and cytokine genes in astrocytes following infection with Theiler's murine encephalomyelitis virus is mediated by the Toll-like receptor 3.

Authors:  Eui Young So; Min Hyung Kang; Byung S Kim
Journal:  Glia       Date:  2006-06       Impact factor: 7.452

7.  Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to Theiler's virus-induced demyelinating disease.

Authors:  L C Pullen; S H Park; S D Miller; M C Dal Canto; B S Kim
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

8.  Activation of MDA5 requires higher-order RNA structures generated during virus infection.

Authors:  Andreas Pichlmair; Oliver Schulz; Choon-Ping Tan; Jan Rehwinkel; Hiroki Kato; Osamu Takeuchi; Shizuo Akira; Michael Way; Giampietro Schiavo; Caetano Reis e Sousa
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

9.  Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared.

Authors:  A L Ford; A L Goodsall; W F Hickey; J D Sedgwick
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

10.  Induction of chemokines in human astrocytes by picornavirus infection requires activation of both AP-1 and NF-kappa B.

Authors:  Daeho Kwon; Alyson C Fuller; Joann P Palma; In-Hong Choi; Byung S Kim
Journal:  Glia       Date:  2004-02       Impact factor: 7.452

View more
  26 in total

Review 1.  Extracellular RNA Sensing by Pattern Recognition Receptors.

Authors:  Megumi Tatematsu; Kenji Funami; Tsukasa Seya; Misako Matsumoto
Journal:  J Innate Immun       Date:  2018-11-07       Impact factor: 7.349

2.  MDA5 Is Critical to Host Defense during Infection with Murine Coronavirus.

Authors:  Zachary B Zalinger; Ruth Elliott; Kristine M Rose; Susan R Weiss
Journal:  J Virol       Date:  2015-09-30       Impact factor: 5.103

3.  Abortively Infected Astrocytes Appear To Represent the Main Source of Interferon Beta in the Virus-Infected Brain.

Authors:  Cathleen Pfefferkorn; Carsten Kallfass; Stefan Lienenklaus; Julia Spanier; Ulrich Kalinke; Martina Rieder; Karl-Klaus Conzelmann; Thomas Michiels; Peter Staeheli
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

4.  Critical role of MDA5 in the interferon response induced by human metapneumovirus infection in dendritic cells and in vivo.

Authors:  M Del Rocío Baños-Lara; Arpita Ghosh; Antonieta Guerrero-Plata
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

5.  Bioinformatics multivariate analysis determined a set of phase-specific biomarker candidates in a novel mouse model for viral myocarditis.

Authors:  Seiichi Omura; Eiichiro Kawai; Fumitaka Sato; Nicholas E Martinez; Ganta V Chaitanya; Phoebe A Rollyson; Urska Cvek; Marjan Trutschl; J Steven Alexander; Ikuo Tsunoda
Journal:  Circ Cardiovasc Genet       Date:  2014-07-16

6.  Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection.

Authors:  Larissa B Thackray; Bimmi Shrestha; Justin M Richner; Jonathan J Miner; Amelia K Pinto; Helen M Lazear; Michael Gale; Michael S Diamond
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

7.  Pattern recognition receptor MDA5 modulates CD8+ T cell-dependent clearance of West Nile virus from the central nervous system.

Authors:  Helen M Lazear; Amelia K Pinto; Hilario J Ramos; Sarah C Vick; Bimmi Shrestha; Mehul S Suthar; Michael Gale; Michael S Diamond
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

8.  The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus.

Authors:  Young-Hee Jin; Wanqiu Hou; Hyun Seok Kang; Chang-Sung Koh; Byung S Kim
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

9.  IRF3 helps control acute TMEV infection through IL-6 expression but contributes to acute hippocampus damage following TMEV infection.

Authors:  Tyler C Moore; Liz Cody; Phyllis M Kumm; Deborah M Brown; Thomas M Petro
Journal:  Virus Res       Date:  2013-10-17       Impact factor: 3.303

10.  Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function.

Authors:  Wanqiu Hou; Young-Hee Jin; Hyun Seok Kang; Byung S Kim
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.